Sun, Feb 1, 2015, 11:52 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

jbennett53 18 posts  |  Last Activity: Jan 27, 2015 4:33 PM Member since: Jul 19, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    No pain after months of use

    by katherine.blackstone Jan 27, 2015 1:01 PM
    jbennett53 jbennett53 Jan 27, 2015 4:33 PM Flag

    Yes......Keep them nice and comfortable you drain every last penny out of all their accounts. The time is coming that this insane medical theft system be scrapped....COMPLETELY.

  • jbennett53 by jbennett53 Jan 22, 2015 8:54 AM Flag

    Anyone ever follow ASTM?? I tracked that one for 15 years thinking, what great science. What a farce! Check out this latest Rubing of the commons. CAMBRIDGE, MA--(Marketwired - November 24, 2014) - Aastrom Biosciences, Inc. (ASTM), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the change of its corporate name to Vericel Corporation (NASDAQ:VCEL) ("Vericel"), effective immediately. The name change has been approved by the company's shareholders. In conjunction with this change, the company has moved its headquarters to Cambridge, Massachusetts, site of its commercial manufacturing facility. Vericel also will maintain operations and several key corporate functions in Ann Arbor, Michigan.

    "Our new corporate name best reflects the nature of our business moving forward as a commercial-stage specialty biologics company with a robust portfolio of marketed and late-stage cell therapy products," said Nick Colangelo, president and chief executive officer of Vericel. "Moving our headquarters to Cambridge also is an important step because it puts us in one of the most vibrant centers for biotechnology and regenerative medicine in the world and allows us to access world-class talent and technologies as we continue to grow our company."

    The company's common stock will begin trading tomorrow, November 25, 2014, at market open on the NASDAQ Capital Market under its new stock ticker symbol "VCEL". The new CUSIP number for the company's common stock is 92346J108 following the name and ticker change.
    The future of NAVB???????????? They need cash.

  • jbennett53 by jbennett53 Jan 18, 2015 1:16 PM Flag

    Ready For Slaughter. I can smell the bacon frying. NAVB no CASH. 65 Cents

  • jbennett53 jbennett53 Jan 3, 2015 12:04 PM Flag

    Anyone here check DNDN? They've cured cancer!! HooRah!! Get in at 13 cents. What a deal!!!

  • Reply to

    late trading volume

    by budrocky22 Jan 2, 2015 8:51 PM
    jbennett53 jbennett53 Jan 3, 2015 11:59 AM Flag


  • Reply to

    Macrophage Therapeutics Conference call 12-15-14

    by tvmanjon Jan 3, 2015 11:29 AM
    jbennett53 jbennett53 Jan 3, 2015 11:57 AM Flag

    Check this out!!! VERY IMPRESSIVE!!!!

    Check This Out!!! VERY Impressive!!!!!!!

    A thumbs-up from a venerable Columbus research institution may give the green light to a company poised to develop a technology that helps create disease-fighting white blood cells.

    Battelle Memorial Institute said Neoprobe Corp.'s CIRA Biosciences Inc. subsidiary is "commercially feasible," Neoprobe (OTC: NEOP) said Tuesday. The pronouncement follows a three-month feasibility study the institute conducted to determine whether the idea was viable.

    Neoprobe, a Dublin-based medical products maker, founded CIRA Biosciences in January but promised to commission Battelle to complete the feasibility study.

    CIRA Biosciences' aim is developing activated cellular therapy, a therapeutic technique developed at Ohio State University. The technique removes lymphocytes, cells in the lymph nodes that help create white blood cells. The technique then stimulates the lymphocytes into creating more white blood cells, which go back inside the patient to fight disease.

    Neoprobe now plans to start trials testing the technique's effectiveness for patients with pancreatic cancer, chronic fatigue syndrome and hepatitis C.

    Neoprobe owns 90 percent of CIRA Biosciences. CIRA LLC, an entity created to hold the technology's patents, owns the rest. Neoprobe makes a number of diagnostic tools, including those to track the spread of cancer through the lymph nodes or to measure blood flow.

  • Reply to

    venting of an actual long

    by greenaxe Dec 30, 2014 10:29 AM
    jbennett53 jbennett53 Dec 30, 2014 11:18 AM Flag

    I was telling you 2 years and more ago about this. There may be great potential. Like RIGS. Like CIRA Biosciences. Problem is the "Unmentionable Ones" run the show. It has become quite obvious that NAVB is not to be. Maybe there is too much money involved that would be harmed. Just like solar power. The reason that we do not have solar is because the electric utilities and gasoline companies would be bankrupted. If solar had been in mass research and production for the last 20 years we would be driving electric cars at about a dollar a gallon equivalent right now. A 3000 square foot home utility bill would be a 1000 a year equivalent. Look to see who would be hurt by a major cancer breakthrough that leaves them out of the game.

  • Reply to

    Many companies with less promising technology

    by tm3912 Dec 18, 2014 8:50 AM
    jbennett53 jbennett53 Dec 18, 2014 10:02 AM Flag

    Yeah....And NEOP is the Germans......OOOPPS!!! I meant NAVB.

  • Reply to


    by itsa1188 Dec 16, 2014 9:31 AM
    jbennett53 jbennett53 Dec 16, 2014 4:23 PM Flag

    I've been here since before this board began. I told you guys well over 2 years ago about the potential. The problem is money and execution. Then there is that other little problem that can't be spoken of. I stand pat at my prediction of 65 cents. Since it is inevitable that we will have a MAJOR market downturn the coincidence of a nadir in both will be really hard on that 65. As to war. Americans love to march off to some foreign land and kill folks. They are suckers. Not a single war we have fought has the cost been justified versus resolving the conflicts differently. You should really read what the West did to the Arabs 100 years ago. Where were the aircraft carriers at Pearl?? It's the same with announcements that cancer has been cured. You send your cash to Wall Street to get slaughtered. You send your son to Iwo Jima to get slaughtered. What's the difference you bought the lie and you reap the pain.

  • Reply to


    by itsa1188 Dec 16, 2014 9:31 AM
    jbennett53 jbennett53 Dec 16, 2014 10:36 AM Flag

    How many times do you need to be slapped?? Stupid American. It's no wonder we have so many wars. Obama or Bush or Clinton or Bush or Nixon or Truman or Roosevelt tell you to go kill and you do it. As you march off the crowds cheer. Sick.

  • jbennett53 jbennett53 Dec 15, 2014 11:05 AM Flag

    It's not a joke takes money to get there from here. 200 million? 300 Million?

  • Reply to


    by b22bru Dec 15, 2014 10:23 AM
    jbennett53 jbennett53 Dec 15, 2014 11:04 AM Flag

    I'm waiting for the 100 million shares ""secondary""" offering to finance all this BS.

  • jbennett53 jbennett53 Dec 12, 2014 10:13 AM Flag

    Sounds to me like the brass is just transferring money to another program. Sounds good. But it's just BS. Waiting for the secondary or triary or cuatrary or cincary or seisary or whatever to 250-300 million shares. Then 400 million..................

  • jbennett53 jbennett53 Dec 11, 2014 9:57 AM Flag

    You have been around for awhile, remember CIRA? What about, RIGS? Maybe this POS will make another run and maybe it won't but one thing is for sure it's been promises promises for 20 years and the equity is selling for 7 cents on the dollar with 10 times the number of shares. How many slaps in the face do you need before you realize all the hype of DD is just that, HYPE. I bought my first shares in 1997 after the crash, so don't give me any BS. I have been here from the first board through Raging Bull to here again. I did not post more than 5 times on those early boards but I've been here long enough to smell the #$%$.

  • Reply to

    Predictions And Where Is DDbuyer???

    by jbennett53 Nov 10, 2014 11:25 AM
    jbennett53 jbennett53 Nov 13, 2014 12:18 PM Flag

    I feel sorry for you. Hope you can cover the losses out of your paycheck. Even worse if this mess goes private or bk. I just love it when the pr comes out that says the common shareholders should expect significant losses. At this point I predict 45 cents. If that coincides with a serious market crash caused by oysters under the bed or a newbola or a boogeyman in the closet or G news what a flash crash to 20 cents ???? is quite possible.

  • jbennett53 jbennett53 Nov 13, 2014 10:37 AM Flag

    Why didn't you sell out May 2011?????

  • If we assume you have 10,000 shares that's 10,000 dollars if you sell now. You can buy the stock back in 6 months or less at 40-45 cents a share and take the wife out for a nice little trip with the 6 grand. On April, 15 you can bank another 1500 in cash on your taxes.You should be paying me for the advice. I told you folks 7 - 10 months ago to sell at 2.50 -3.00 a share and predicted 65 cents. This is definitely going to 45 cents and maybe much worse. I will keep you posted on an occasional basis.

  • Reply to

    No shares moving, squeeze is coming

    by hughes.markd Nov 4, 2014 1:07 PM
    jbennett53 jbennett53 Nov 4, 2014 3:01 PM Flag

    Wait until losses are reported. Then tell me, ""shorties are stuck"". You would have made a good general at Antietam or maybe Verdun. Gallipoli??? How much time are you longs going to give this loser? Maybe there will be a turn in 2016. And maybe not. One thing is sure, there will be a lot of bodies left in the trenches of the long when this is over.

1.87-0.10(-5.08%)Jan 30 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.